{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T05:31:41Z","timestamp":1734672701798,"version":"3.32.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,19]]},"DOI":"10.7759\/cureus.76018","type":"journal-article","created":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T17:15:52Z","timestamp":1734628552000},"source":"Crossref","is-referenced-by-count":0,"title":["An Unusual Case of Chylous Ascites"],"prefix":"10.7759","author":[{"given":"Thanda","family":"Aung","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mia","family":"Celestin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sherona","family":"Bau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sammy","family":"Saab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12641","article-title":"Immunology of IgG4-related disease","volume":"181","author":"Della-Torre E","year":"2015","unstructured":"Della-Torre E, Lanzillotta M, Doglioni C. Immunology of IgG4-related disease. Clin Exp Immunol. 2015, 181:191-206. 10.1111\/cei.12641","journal-title":"Clin Exp Immunol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.205526","article-title":"IgG4-related disease: what a hematologist needs to know","volume":"104","author":"Chen LY","year":"2019","unstructured":"Chen LY, Mattman A, Seidman MA, Carruthers MN. IgG4-related disease: what a hematologist needs to know. Haematologica. 2019, 104:444-55. 10.3324\/haematol.2018.205526","journal-title":"Haematologica"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1186\/s43066-024-00354-3","article-title":"Filarial chylous ascites with chylothorax: challenge of diagnosis and management case\r\nreport","volume":"14","author":"Elhadidy A","year":"2024","unstructured":"Elhadidy A, Elrefaay M, Elsheshiny H, Elnagdy F. Filarial chylous ascites with chylothorax: challenge of diagnosis and management case\r\nreport. Egyptian Liver J. 2024, 14:1-6. 10.1186\/s43066-024-00354-3","journal-title":"Egyptian Liver J"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/art.39132","article-title":"International consensus guidance statement on the management and treatment of IgG4-related disease","volume":"67","author":"Khosroshahi A","year":"2015","unstructured":"Khosroshahi A, Wallace ZS, Crowe JL, et al.. International consensus guidance statement on the management and treatment of IgG4-related disease. Arthritis Rheumatol. 2015, 67:1688-99. 10.1002\/art.39132","journal-title":"Arthritis Rheumatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204907","article-title":"The diagnostic utility of serum IgG4 concentrations in IgG4-related disease","volume":"74","author":"Carruthers MN","year":"2015","unstructured":"Carruthers MN, Khosroshahi A, Augustin T, Deshpande V, Stone JH. The diagnostic utility of serum IgG4 concentrations in IgG4-related disease. Ann Rheum Dis. 2015, 74:14-8. 10.1136\/annrheumdis-2013-204907","journal-title":"Ann Rheum Dis"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-012513-104708","article-title":"IgG4-related disease","volume":"9","author":"Mahajan VS","year":"2014","unstructured":"Mahajan VS, Mattoo H, Deshpande V, Pillai SS, Stone JH. IgG4-related disease. Annu Rev Pathol. 2014, 9:315-47. 10.1146\/annurev-pathol-012513-104708","journal-title":"Annu Rev Pathol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200103083441005","article-title":"High serum IgG4 concentrations in patients with sclerosing pancreatitis","volume":"344","author":"Hamano H","year":"2001","unstructured":"Hamano H, Kawa S, Horiuchi A, et al.. High serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med. 2001, 344:732-8. 10.1056\/NEJM200103083441005","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(19)30017-7","article-title":"Management of IgG4-related disease","volume":"1","author":"Zhang W","year":"2019","unstructured":"Zhang W, Stone JH. Management of IgG4-related disease. Lancet Rheum. 2019, 1:e55-65. 10.1016\/S2665-9913(19)30017-7","journal-title":"Lancet Rheum"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2012-302886","article-title":"Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience","volume":"62","author":"Hart PA","year":"2013","unstructured":"Hart PA, Topazian MD, Witzig TE, et al.. Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience. Gut. 2013, 62:1607-15. 10.1136\/gutjnl-2012-302886","journal-title":"Gut"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2014.223","article-title":"Type 1 autoimmune pancreatitis and IgG4-related sclerosing cholangitis is associated with extrapancreatic organ failure, malignancy, and mortality in a prospective UK cohort","volume":"109","author":"Huggett MT","year":"2014","unstructured":"Huggett MT, Culver EL, Kumar M, et al.. Type 1 autoimmune pancreatitis and IgG4-related sclerosing cholangitis is associated with extrapancreatic organ failure, malignancy, and mortality in a prospective UK cohort. Am J Gastroenterol. 2014, 109:1675-83. 10.1038\/ajg.2014.223","journal-title":"Am J Gastroenterol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/art.39686","article-title":"IgG4-related disease: retrospective analysis of one hundred sixty-six patients","volume":"68","author":"Sekiguchi H","year":"2016","unstructured":"Sekiguchi H, Horie R, Kanai M, Suzuki R, Yi ES, Ryu JH. IgG4-related disease: retrospective analysis of one hundred sixty-six patients. Arthritis Rheumatol. 2016, 68:2290-9. 10.1002\/art.39686","journal-title":"Arthritis Rheumatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209368","article-title":"Efficacy of abatacept for IgG4-related disease over 8\u2005months","volume":"75","author":"Yamamoto M","year":"2016","unstructured":"Yamamoto M, Takahashi H, Takano K, et al.. Efficacy of abatacept for IgG4-related disease over 8\u2005months. Ann Rheum Dis. 2016, 75:1576-8. 10.1136\/annrheumdis-2016-209368","journal-title":"Ann Rheum Dis"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab950","article-title":"Therapeutic potential of the interleukin-4\/interleukin-13 inhibitor dupilumab for treating IgG4-related disease","volume":"61","author":"Nakajima I","year":"2022","unstructured":"Nakajima I, Taniguchi Y, Tsuji H, Mizobuchi T, Fukuda K. Therapeutic potential of the interleukin-4\/interleukin-13 inhibitor dupilumab for treating IgG4-related disease. Rheumatology (Oxford). 2022, 61:e151-3. 10.1093\/rheumatology\/keab950","journal-title":"Rheumatology (Oxford)"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-216945","article-title":"Dupilumab as a potential steroid-sparing treatment for IgG4-related disease","volume":"81","author":"Della-Torre E","year":"2022","unstructured":"Della-Torre E, Lanzillotta M, Yacoub MR. Dupilumab as a potential steroid-sparing treatment for IgG4-related disease. Ann Rheum Dis. 2022, 81:e24. 10.1136\/annrheumdis-2020-216945","journal-title":"Ann Rheum Dis"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0183844","article-title":"Long-term efficacy and safety of rituximab in IgG4-related disease: data from a French nationwide study of thirty-three patients","volume":"12","author":"Ebbo M","year":"2017","unstructured":"Ebbo M, Grados A, Samson M, et al.. Long-term efficacy and safety of rituximab in IgG4-related disease: data from a French nationwide study of thirty-three patients. PLoS One. 2017, 12:e0183844. 10.1371\/journal.pone.0183844","journal-title":"PLoS One"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-28405-x","article-title":"Factors in glucocorticoid regimens associated with treatment response and relapses of IgG4-related disease: a multicentre study","volume":"8","author":"Shirakashi M","year":"2018","unstructured":"Shirakashi M, Yoshifuji H, Kodama Y, et al.. Factors in glucocorticoid regimens associated with treatment response and relapses of IgG4-related disease: a multicentre study. Sci Rep. 2018, 8:10262. 10.1038\/s41598-018-28405-x","journal-title":"Sci Rep"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev438","article-title":"Predictors of disease relapse in IgG4-related disease following rituximab","volume":"55","author":"Wallace ZS","year":"2016","unstructured":"Wallace ZS, Mattoo H, Mahajan VS, et al.. Predictors of disease relapse in IgG4-related disease following rituximab. Rheumatology (Oxford). 2016, 55:1000-8. 10.1093\/rheumatology\/kev438","journal-title":"Rheumatology (Oxford)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/317584-an-unusual-case-of-chylous-ascites","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T17:15:53Z","timestamp":1734628553000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/317584-an-unusual-case-of-chylous-ascites"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,19]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.76018","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12,19]]}}}